What does Addex Therapeutics do and what are its main business segments?

What factors drove the changes in Addex Therapeutics's revenue and profit?

Did Addex Therapeutics beat or miss consensus estimates last quarter?

What guidance did Addex Therapeutics's management provide for the next earnings period?

What is the revenue and EPS growth rate for Addex Therapeutics year over year?

What were the key takeaways from Addex Therapeutics's earnings call?

What were the key takeaways from Addex Therapeutics’s earnings call?

What is the market's earnings forecast for Addex Therapeutics next quarter?

- **GABAB PAM for Cough**: IND-enabling studies ready; potential best-in-class efficacy with 70% cough reduction in preclinical models. 
- **Dipraglurant Repositioning**: Fast onset, short half-life; clinical studies preparation with Lund University/Sinntaxis. 
- **Stalicla Progress**: Autism patient stratification studies advancing; mavoglurant out-licensing and Series C financing in pipeline. 
- **Financial Sustainability**: CHF 2.2 million cash runway; external funding needed for unpartnered programs. 
- **Competitive Insights**: CCR5 modulators in stroke recovery trials (e.g., maraviroc) provide learnings for adaptive rewiring mechanisms. 
- **Indivior Milestones**: Up to USD 330 million in potential payments; royalty rates 5-10% on net sales. 


**【CEO Summary Section】**
- **Pipeline Progress**: Advanced GABAB PAM program for chronic cough, with IND-enabling studies ready to commence (subject to financing). Repositioned dipraglurant for post-stroke recovery, with preclinical profiling and clinical study preparation underway. Neurosterix's M4 PAM schizophrenia program nearing Phase I. Stalicla advancing patient stratification studies in autism spectrum disorders. 
- **Financial Update**: Q3 2025 cash balance of CHF 2.2 million, providing runway through mid-2026. Reduced cash burn post-Neurosterix spinout. Unpartnered programs require external funding for clinical progression. 
- **Collaboration Highlights**: Indivior completed IND-enabling studies for GABAB PAM in substance use disorders, with potential milestones worth up to USD 330 million. Exclusive license for mGlu5 inhibitors in brain injury recovery via Sinntaxis/University of Lund collaboration. 

**【CFO Financial Commentary】**
- **Revenue**: Q3 2025 income of CHF 0.1 million (patent maintenance and services). 
- **Expenses**: R&D (CHF 0.2 million), G&A (CHF 0.5 million), and equity method loss from Neurosterix (CHF 0.9 million). 
- **Balance Sheet**: Total assets CHF 7.4 million (cash CHF 2.2 million, noncurrent assets CHF 5 million). Liabilities stable at CHF 1.4 million. 

**【Q&A Key Highlights】**
- **Chronic Cough Market**: 50% of patients unresponsive to P2X3 inhibitors; GABAB PAM addresses central and peripheral mechanisms, with potential best-in-class efficacy. 
- **Stalicla Strategy**: Series C financing for Phase II studies in autism; mavoglurant out-licensing discussions. IPO considerations under evaluation. 
- **Stroke Recovery Competition**: CCR5 modulators (e.g., maraviroc) in CAMAROS trial; learnings from sensory/motor recovery endpoints to inform dipraglurant trial design. 
- **Indivior Collaboration**: IND submission for GABAB PAM in substance use disorders expected in 2026. Addex eligible for tiered royalties on net sales. 


Addex Therapeutics Ltd (ADXN) Q3 2025 Earnings Call Transcript

- **$65M Neurosterix Spin-Out:** CHF5M cash + 20% equity stake; removes financing overhang for core programs.
- **GABAB PAM Pipeline:**
  - Chronic cough candidate shows 30x safety margin; IND-enabling studies in 2025.
  - Indivior partner advancing substance use disorder program with IND in 2024.
- **Dipraglurant Repositioning:** Post-stroke recovery Phase 2a planned; preclinical data supports neuroplasticity benefits.
- **Financial Strength:** CHF3.3M cash runway to mid-2026; 20% stake in $65M-backed Neurosterix.

**【CEO Opening Remarks】**
- Launched Neurosterix with $65M Series A financing, securing CHF5M cash and 20% equity stake.
- Partnered with Indivior for GABAB PAM in substance use disorders, with IND-enabling studies underway.
- Regained rights to Phase 2 asset ADX-71149 from J&J, with 280kg API transferred for potential collaborations.
- 2024 cash balance: CHF3.3M, providing runway through mid-2026.

**【Mikhail Kalinichev - R&D Update】**
- **Dipraglurant (mGluR5-NAM):** Repositioned for post-stroke recovery; preclinical data shows improved neuroplasticity and functional recovery. IND-enabling studies planned.
- **GABAB PAM for Chronic Cough:** Preclinical efficacy (1mg/kg ED50) and tolerability superior to baclofen; IND-enabling studies to start in 2025.
- **Indivior Collaboration:** Selected GABAB PAM candidate for substance use disorders; IND-enabling studies initiated in H2 2024.

**【CEO Financial Review】**
- Continuing operations revenue: CHF0.4M (vs. CHF1.6M in 2023), driven by Indivior collaboration completion.
- R&D expenses: CHF0.9M (down 20% YoY); G&A: CHF2.3M (down 14% YoY).
- Net cash burn reduced post-Neurosterix spin-out; 20% equity stake in Neurosterix provides upside exposure.

**【Q&A Highlights】**
- **Neurosterix Structure:** 4 programs (M4 PAM, mGluR7-NAM, mGluR2-NAM, undisclosed CNS asset) focused on neuropsychiatry.
- **Dipraglurant Strategy:** Phase 2a planned to assess neuroplasticity modulation in post-stroke patients; potential for TBI applications.
- **ADX-71149 Future:** Exploring collaborations for unpartnered programs; high-quality dataset and materials available for repurposing.

Actual	-19.9139	-15.8164	-15.7834	-10.5033	-10.5119	-18.5267	-14.4602	-16.3027	-18.2713	-23.8906	11.4183	-27.5968	-5.367	-5.4936	-4.1145		-1.3452	11.3805	-2.6853			-3.0164	-1.4982
Forecast					-13.1291	-15.7515	-17.0538	-12.9835	-10.3265	-2.7059	-1.8564	-1.0314	-1.0314	-0.8251	-0.6623	-0.6623	-0.4415	-1.4239	-1.4197	-1.4197	-4.2591	0	0	0
Surprise	0.00%	0.00%	0.00%	0.00%	+19.93%	-17.62%	+15.21%	-25.56%	-76.94%	-782.91%	+715.08%	-2575.66%	-420.36%	-565.81%	-521.24%	0.00%	-204.69%	+899.25%	-89.15%	0.00%	0.00%	0.00%	0.00%	0.00%

ADXN

ADXN fundamentals

ADXN Q4 2025 Earnings Preview

Earnings Call

You can ask Aime

ADXN

ADXN fundamentals

ADXN Q4 2025 Earnings Preview

Earnings Call

ADXN Earnings Call Summary for Q4/2025 Apr 6, 2026

ADXN Earnings Call Summary for Q3/20255:00 PM on Dec 4, 2025

ADXN Earnings Call Summary for Q2/20254:00 PM on Oct 1, 2025

ADXN Earnings Call Summary for Q1/20254:00 PM on Jun 19, 2025

ADXN Earnings Call Summary for Q4/202410:00 AM on Apr 25, 2025

You can ask Aime